Successful management of an extremely premature infant with congenital candidiasis

Sota Iwatani1, Yuko Murakami2, Masami Mizobuchi3

  • 1Department of Neonatology, Hyogo Prefectural Kobe Children's Hospital Perinatal Center, Suma-Ku, Kobe-Shi, Hyogo, Japan ; These authors contributed equally to this work.

AJP Reports
|July 18, 2014
PubMed

Insights

This case study reports a rare instance of congenital candidiasis in an extremely premature infant. Early diagnosis via skin lesions and prompt antifungal treatment led to a successful outcome without significant complications.

Area of Science:

  • Neonatology
  • Infectious Diseases
  • Dermatology

Background:

  • Congenital candidiasis is an extremely rare neonatal infection.
  • Reported cases in term and preterm infants are fewer than 100.
  • This condition can manifest with diverse clinical symptoms.

Observation:

  • A male infant born at 25 weeks' gestation presented with diffuse erythematous papules.
  • Candida albicans was detected in skin, pharyngeal mucus, gastric fluid, and tracheal aspirate.
  • Histopathology confirmed Candida albicans mycelial invasion of the umbilical cord.

Findings:

  • Blood cultures were negative, indicating a localized infection.
  • The infant received prompt antifungal therapy.
  • Skin lesions showed marked improvement following treatment.

Implications:

  • Characteristic skin lesions are crucial for early diagnosis of Candida infections in neonates.
  • Early and effective antifungal treatment can lead to favorable outcomes in extremely premature infants.
  • This case highlights successful management of a rare neonatal fungal infection.

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
654
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
96
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
62
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
114
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
400